Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
BVS Stock Chart & Stats
$8.64
-$0.12(-1.26%)
At close: 4:00 PM EST
$8.64
-$0.12(-1.26%)
Day’s Range― - ―
52-Week Range$5.81 - $9.98
Previous CloseN/A
Volume116.12K
Average Volume (3M)257.41K
Market Cap
$718.46M
Enterprise Value$842.17M
Total Cash (Recent Filing)$51.24M
Total Debt (Recent Filing)$311.35M
Price to Earnings (P/E)21.8
Beta0.92
Next Earnings
May 12, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding67,368,050
10 Day Avg. Volume219,442
30 Day Avg. Volume257,406
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue1.48
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda7.98
Forecast
1Y Price Target
$15.00Price Target Upside73.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.77
Revenue Forecast (FY)$604.18M
Bulls Say, Bears Say
Bulls Say
Cash Flow And Reinvestment CapacityRobust operating and free cash flow generation strengthened financial flexibility, enabling greater investment in commercial expansion and research and development to support future growth.
Profitability And Margin ExpansionAnalyst notes adjusted earnings and operating profit beat expectations driven by a favorable product mix and disciplined spending, indicating potential for sustained margin improvement.
Revenue Growth From Core ProductsAnalyst attributes revenue acceleration to strong sales of pain treatments and restorative therapies, led by Durolane and Exogen, supporting upside to consensus sales.
Bears Say
Balance Sheet Leverage RiskMaterial debt relative to cash creates leverage risk that could limit strategic flexibility and increase vulnerability to adverse market conditions.
Capital Equipment Demand WeaknessWeak demand for Ultrasonics capital equipment and timing issues with international distributor orders constrained Surgical Solutions growth, posing downside risk to revenue momentum.
Execution And Suitability ConcernsAnalyst classifies suitability and risk as aggressive due to concerns about execution and leverage management, which could amplify share price volatility.
Bioventus News
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $5.81 and its highest was $9.98 in the past 12 months.
What is Bioventus’s market cap?
Bioventus’s market cap is $718.46M.
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is May 12, 2026 which is in 49 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Mar 05, 2026. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.216 by $0.024.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is 0.11.
How many shares outstanding does Bioventus have?
Bioventus has 67,368,050 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.24 in its last earnings report, beating expectations of $0.216. Following the earnings report the stock price went up 7.438%.
Which hedge fund is a major shareholder of Bioventus?
Currently, no hedge funds are holding shares in BVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (73.61% Upside)
$15.00 (73.61% Upside)
Hedge Fund Trend
Increased
By 11.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.17%
12-Months-Change
Fundamentals
Return on Equity
4.97%
Trailing 12-Months
Asset Growth
-8.82%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong underlying progress: accelerating organic growth (10% Q4), substantial margin expansion, record quarterly cash from operations and successful pilot validation for PNS and PRP with a committed incremental investment plan. Management also communicated concrete deleveraging progress and clear 2026 guidance. Near-term headwinds include FX impacts, distributor/timing effects that contributed to Q4 and are expected to pressure Q1, a headline revenue increase that is modest (+3%) versus organic growth, and a Q4 Restorative Therapies decline driven by a divestiture. Overall, the positive operational and financial momentum, successful pilots and disciplined capital allocation outweigh the transitory challenges highlighted for the early part of 2026.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$15.00
▲(73.61% Upside)
Technical Analysis
Ownership Overview
31.78% Insiders
8.13% Mutual Funds
46.35% Other Institutional Investors
5.35% Public Companies and
Individual Investors